Slide 1: FY26 Result Presentation
FY26 Result Presentation From Archive to Architecture Mach7 Technologies Limited | ASX: M7T | 28 August 2026 1
Slide 2: Disclaimer
Disclaimer “Forward looking” statements Summary of information: This presentation contains general and background information about Mach7 unknown risks, uncertainties and other factors, many of which are outside the control of M7T. Past Technologies Limited (“M7T”) activities current as at the date
Slide 3: We complete the patient picture with the patient's pictures
FROM ARCHIVE TO ARCHITECTURE We complete the patient picture with the patient's pictures. Imaging data, unified, organized, and secure wherever care happens. Electronic Health Record (EHR) -integrated, under the customer's control “From Pixel To Point Of Care ” © 2026 Mach7 Technologies Limited · AS
Slide 4: Our advantage is speed
Our advantage is speed Mach 7 is seven times the speed of sound Roughly 8,600 km/h. We took the name as a unit of measure, and we use it internally as a standard for pace. 01 · SPEED 02 · LEARNING 03 · AI Measured in learning The compounding part Our accelerator Our edge is how quickly we learn and
Slide 5: Agenda
Agenda 01 02 03 Teri Thomas Action The engine The horizon CEO FY26: what we reset, and Where growth comes What compounds from what it produced from: new customer here, and the discipline we relationships, partnerships, hold ourselves to FY26 result overview and a happy and growing install base Shawn
Slide 6: Action
01 Action FY26 was a reset year. We changed this business. © 2026 Mach7 Technologies Limited · ASX: M7T 6
Slide 7: We made hard decisions. They are beginning to pay off.
01 · ACTION We made hard decisions. They are beginning to pay off. A broad restructure: four major changes, each taken deliberately, with costs absorbed in FY26. A market -leading customer engagement model A rebuilt leadership team Designated cross -functional teams per customer, executive sponsorsh
Slide 8: A materially stronger leadership team
01 · ACTION A materially stronger leadership team Seven senior leaders appointed within the last twelve months, with product, support and engineering unified under one technical leader. Brian Wehrle Shawni Hadfield Todd Stallard Mike Moore CHIEF TECHNOLOGY INTERIM CHIEF EVP, COMMERCIAL VP GROWTH & O
Slide 9: From 68.7 to 73.6
01 · ACTION Independently measured, and improving KLAS is the industry's most recognised independent benchmark of customer satisfaction in healthcare IT. "We love you guys and we feel very connected to you. We wish all of our 86.6 vendors and partners were like Mach7." Systems Engineer · imaging gro
Slide 10: Welcoming new customer relationships
01 · ACTION Welcoming new customer relationships Engaging at Mach7 speed Shortening the time from contract to customer outcomes (and revenue for us). FIRST FLAMINGO CUSTOMER FASTEST IN COMPANY HISTORY A new customer live on Flamingo Teleradiology selection to live record Our orchestration module, so
Slide 11: Converting one-off licences into an annuity, better revenue base
01 · ACTION Converting one -off licences into an annuity, better revenue base BEFORE We’ve begun shifting customers from capital licences to Capital licences subscription. Each conversion replaces a lumpy, less predictable Large, irregular, hard to forecast where every expansion is a sale with more
Slide 12: FY26 result overview
01 · ACTION FY26 FULL - YEAR RESULT FY26 result overview Financial highlights for the year ended 30 June 2026 © 2026 Mach7 Technologies Limited · ASX: M7T 12
Slide 13: Predominantly recurring revenue, lower cost base, strong balance sheet
FY26 FINANCIAL REVIEW Predominantly recurring revenue, lower cost base, strong balance sheet 1 Met FY26 guidance. Revised guidance reflected impact of geopolitical conflict on capital deal conversion and improved cost control. 2 Stronger H2 FY26. Demonstrated progress against strategic priorities an
Slide 14: FY26 financial summary
BY THE NUMBERS FY26 financial summary REVENUE RECURRING REVENUE 2 CARR 3 ARR RUN RATE 4 A$27.9M A$23.4M A$25.5M A$23.5M −A$5.9M or −17 % on PCP 1 −A$1.9M or −8% on PCP −A$2.7M or −9% on PCP +A$1.7M or 8% on PCP 84% of revenue (PCP: 75%) Constant currency Constant currency OPERATING EXPENSES 5 EBITDA
Slide 15: ARR run-rate recorded solid growth in constant currency
REVENUE ARR run -rate recorded solid growth in constant currency REVENUE(A$M) H1 FY26 H2 FY26 Subscription revenue 5.5M 6.3M Total revenue A$27.9M , down 17% on PCP (FY25: A$33.8M), largely due to lower capital licence expansions and softer professional services. Momentum improved Maintenance & Supp
Slide 16: Restructured cost base supports improved operating leverage
EARNINGS & CASH FLOW Restructured cost base supports improved operating leverage EARNINGS (A$M) 1 FY26 FY25 $ CHG % CHG Gross margin held at 93% , consistent with the efficiency Revenue 27.9M 33.8M (5.9M ) (17 %) and scalability of the platform. Cost of sales (2.1M) (2.0M ) (0.1M) 3% OPEX down 16% f
Slide 17: H2 FY26 demonstrated progress across strategic priorities
MOMENTUM BUILT ACROSS FY26 H2 FY26 demonstrated progress across strategic priorities SALES ORDERS (TCV, A$M) REVENUE (A$M) OPEX (A$M) 15.1 14.8 13.7 14.3 13.8 0.7 1.2 8.4 14.1 12.6 H1 FY26 H2 FY26 H1 FY26 H2 FY26 H1 FY26 H2 FY26 Operating expenses Restructuring costs • FY26 sales orders of A$23.5M w
Slide 18: Closing the book on the reset year
01 · ACTION Closing the book on the reset year Three distinct challenges impacted FY26 numbers, resolved and behind us OUTLIERS A PRESENTATION ISSUE THE REAL SIGNAL Cleaned customer base Currency impacts The underlying base grew Largely cycled the loss of two key Majority of our business operates in
Slide 19: The engine
02 The engine Where the next phase of growth is generated, and why it’s better quality than before © 2026 Mach7 Technologies Limited · ASX: M7T 19
Slide 20: Imaging data is everywhere, and sometimes it's trapped.
02 · THE ENGINE Imaging data is everywhere, and sometimes it’s trapped. Medical imaging drives diagnosis and treatment across almost every specialty. Yet the data remains fragmented, duplicated, and “ We found up to 18 separate copies locked inside proprietary systems. Every incomplete record and of
Slide 21: A large market, solid potential
02 · THE ENGINE A large market, solid potential We are positioned to sell to nearly every entity that engages in healthcare. We focus on those who benefit most from Mach7. This includes a cademics , IDNs, teleradiology, imaging centers and even patients. THE MARKET SEGMENTED US$5.7b → US$7.3b Total
Slide 22: The shift that makes this position valuable
02 · THE ENGINE The shift that makes this position valuable Software used to be something people learned to use. It is becoming something that learns how people work. That functions safely if the data underneath is accessible, connected and usable. AI becomes a consumer of Value moves from storage t
Slide 23: One architecture, adopted a piece at a time
02 · THE ENGINE One architecture, adopted a piece at a time ENTERPRISE DATA MANAGEMENT ENTERPRISE DIAGNOSTIC VIEWING DATA WORKFLOW ORCHESTRATION Vendor Neutral Archive eUnity Enterprise Viewer Flamingo Modules Consolidates imaging across the Our highest -rated product, the zero - Rules -based routin
Slide 24: Flamingo
02 · THE ENGINE THE LAUNCH SCOPE Flamingo Foundation Our next -generation architecture One core vendor -neutral next -generation platform built to scale under evolves the platform customers every workflow with seamless EHR connectivity already run. It modernises from Storage within: containerised de
Slide 25: One flexible and comprehensive viewer
02 · THE ENGINE One flexible and comprehensive viewer Diagnostic viewing Advanced visualisation Inside the clinical record Patient access Full fidelity in any browser, with no Multi-planar and 3D reading Images where the clinician already Patients view their own images in installed software works, o
Slide 26: Imaging goes way beyond radiology
02 · THE ENGINE Imaging goes way beyond radiology Clinical images are everywhere. Too many remain trapped outside the EHR on departmental systems and devices. Flamingo connects them. Dermatology Ophthalmology Endoscopy Pathology Wound care Surgery Point -of-care ultrasound Completing the patient’s r
Slide 27: How growth compounds: the Mach7 Loop
Customer Delight our advocates 02 · THE ENGINE customer refer How growth compounds: the Mach7 Loop Customer - KLAS and centric top innovation reputation New Sales 01 02 03 04 05 Delight the Stories and Independent Selling gets easier Fund more customer references scores rise Lower cost of sale on in
Slide 28: Widening the front through partners
02 · THE ENGINE Widening the front through partners A small number of deep relationships rather than a long tail of low -return/high -effort partnerships Cloud and infrastructure Clinical record integration Regional resellers Co -selling and marketplace procurement with Integrated value -add workflo
Slide 29: The horizon
03 The horizon © 2026 Mach7 Technologies Limited · ASX: M7T 29
Slide 30: Stabilise, prove, compound
03 · THE HORIZON Stabilise , prove, compound Three phases: the first largely behind us, the second the year in front of us, and the third is the company we are building. CURRENT AMBITION Prove the growth engine Compound and lead Develop and sell new modules. While we Become the default orchestration
Slide 31: The shape of a compounder
03 · THE HORIZON The shape of a compounder These are the characteristics of a strong software business like ours High -quality revenue Operating leverage A predominantly recurring base at high gross margin, with expansion A cost base that has been reset and held, so that incremental revenue revenue
Slide 32: What to watch in FY27
03 · THE HORIZON What to watch in FY27 Our areas of focus and how we measure our progress ARR growth New customer wins Module adoption OPEX discipline Expand and grow our Increased demand Customers paying for new Disciplined spend focused on recurring base converting into new Flamingo modules ROI an
Slide 33: Contact Us
Contact Us Investor Relations, Mach7 Françoise Debelak Dixon +61 (0) 412 292 977 ir@mach7t.com Registered Office: Suite 2, Level 11, 385 Bourke St, Melbourne, VIC 3000 This document was authorised for release to the ASX by Teri Thomas, Managing Director and Chief Executive Officer Mach7 Technologies